Valuation: Scancell Holdings plc

Market Cap 100M 133M 117M 109M 188M 12.77B 190M 1.29B 506M 6.3B 500M 489M 21.79B P/E 2026 *
-6.28x
P/E 2027 * -11.9x
Enterprise Value 110M 147M 129M 120M 207M 14.1B 210M 1.43B 558M 6.96B 552M 540M 24.06B EV / Sales 2026 *
88.4x
EV / Sales 2027 * 48.3x
Free-Float
96.34%
Yield 2026 *
-
Yield 2027 * -
1 day+2.55%
1 week-27.25%
Current month-44.91%
1 month-47.61%
3 months-24.39%
6 months-27.93%
Current year-2.63%
1 week 9.3
Extreme 9.3
14
1 month 9.3
Extreme 9.3
18.5
Current year 9.3
Extreme 9.3
29.5
1 year 7.86
Extreme 7.8555
29.5
3 years 7.26
Extreme 7.26
29.5
5 years 7.26
Extreme 7.26
29.5
10 years 0.11
Extreme 0.1118
29.5
Manager TitleAgeSince
Chief Executive Officer 64 2024-11-17
Chief Executive Officer 69 2021-07-27
Director of Finance/CFO 50 2026-04-23
Director TitleAgeSince
Director/Board Member 69 2010-11-16
Director/Board Member 74 2019-10-22
Director/Board Member 64 2020-09-23
Date Insider Type Main position Quantity % Market Cap.
9/16/25
Vulpes Investment Management Pte Ltd.
BuyCompany 3,150,000 0.3038%
8/8/25
Vulpes Investment Management Pte Ltd.
BuyCompany 102,236 0.0099%
8/4/25
Vulpes Investment Management Pte Ltd.
BuyCompany 4,400,000 0.4244%
Change 5-day change 1-year change 3-year change Capi.($)
+2.55%-27.25%-1.13%-1.63% 130M
+2.08%-1.48%-1.34%+14.07% 46.86B
-0.61%+4.26%+404.75%+647.20% 40.23B
0.00%+4.93%+10.66%+55.56% 36.23B
+2.48%+4.57%+7.82%-5.05% 34.72B
+0.62%+1.65%+5.41%+43.89% 27.89B
-2.00%+11.64%+30.09%+136.81% 16.79B
-0.17%+0.66% - - 16.74B
+0.78%-4.78%-2.68%+9.96% 13.12B
+1.82%+1.56%-11.01%-30.15% 12.7B
Average +0.78%-2.04%+49.17%+96.74% 24.54B
Weighted average by Cap. +0.74%+1.04%+75.91%+139.07%

Financials

2026 *2027 *
Net sales 1.25M 1.66M 1.46M 1.36M 2.35M 160M 2.38M 16.18M 6.32M 78.76M 6.24M 6.11M 272M 2.4M 3.19M 2.81M 2.61M 4.51M 306M 4.57M 31.06M 12.13M 151M 11.99M 11.73M 523M
Net income -19.23M -25.59M -22.5M -20.94M -36.12M -2.45B -36.59M -249M -97.23M -1.21B -96.07M -94M -4.19B -8.24M -10.96M -9.64M -8.97M -15.47M -1.05B -15.67M -107M -41.64M -519M -41.14M -40.26M -1.79B
Net Debt 10.42M 13.86M 12.18M 11.34M 19.56M 1.33B 19.82M 135M 52.66M 656M 52.03M 50.91M 2.27B 15.87M 21.12M 18.57M 17.29M 29.81M 2.03B 30.2M 205M 80.24M 1B 79.29M 77.58M 3.46B
Logo Scancell Holdings plc
Scancell Holdings plc is a clinical-stage biopharmaceutical company. The Company is engaged in studying the human adaptive immune system, to generate medicines to treat unmet needs in cancer. The Company is building a pipeline of products by utilizing its four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies. Its product pipeline includes Modi-1, Modi-2, SCIB1 & iSCIB1+, SCIB2, SC129, SC134, SC2811, SC27, and others. Modi-1 is the first therapeutic vaccine candidate from the Company’s Moditope platform, which targets citrullinated peptides from two different proteins which have been combined to reduce the possibility of tumor escape and have each been conjugated to a toll-like receptor (TLR) 1/2 agonist, which acts as an adjuvant. Modi-2, which targets homocitrullinated cancer antigens, is the second therapeutic vaccine candidate from the Company’s Moditope platform and has the potential to address different cancer indications to Modi-1.
Employees
60
Date Price Change Volume
26-07-27 GBX 9.640 +2.55% 19,137,685
26-07-24 GBX 9.400 -10.48% 21,654,800
26-07-23 GBX 10.50 -17.65% 18,012,510
26-07-22 GBX 12.75 -5.56% 1,344,509
26-07-21 GBX 13.50 0.00% 686,674
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.0940GBP
Average target price
0.2550GBP
Spread / Average Target
+171.28%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SCLP Stock